Allergic diseases affect over 20% of the population today

Nearly 35% of respiratory allergy sufferers experience both allergic rhinitis and asthma, which impact their quality of life 1,2. Standard diagnostic methods such as skin tests are at times impossible or difficult to perform, have limited reliability and must be performed by trained Allergy and Asthma Specialists. Similarly, laboratory blood tests for specific immunoglobulin E (sIgE) levels have a long turnaround time until results, thus delaying treatment up to several days and requiring multiple visits. Fast and accurate diagnosis of allergies is therefore key to relieve symptoms and to guide the best treatment.

The first point-of-care molecular allergy diagnostics with semi-quantitative IgE results

Abionic has developed the IVD CAPSULE Aeroallergen blood test, a unique, rapid, easy-to-operate serological IgE test at the point of care, composed of 7 key allergens to help diagnose allergic asthma 3,4.

Abionic’s IVD CAPSULE Aeroallergen blood test:

Excellent correlation between test results on the abioSCOPE® and laboratory reference methods

IgE assays reached an agreement of 94.6% on the abioSCOPE® vs the reference laboratory method

Figure 1. Method comparison: sIgE on abioSCOPE (whole blood) vs the laboratory gold standard (ImmunoCAP) (plasma). Green squares denote RAST class agreements.
Table 1. An allergy expert panel had access to all patients’ medical records, with sIgE concentration either from abioSCOPE® or ImmunoCAP (blinded method). n: number of patients; P: number of cases where the panel agreed on the presence of an allergy; N: agreement that the patient was not allergic; D: discordant decisions.


The abioSCOPE® optimises the clinical management of patients by enabling healthcare practitioners to immediately prescribe an adequate treatment. The first results are available within 12 minutes at the point of care, enabling physicians to obtain actionable results during the first patient visit.

The respiratory allergy panel on the abioSCOPE® simultaneously analyses 7 different allergens: Phl p 1, Phl p 5, Der p 1, Der p 2, Alt a 1, Fel d 1 and Can f 1.

The test can be performed easily by any healthcare practitioner after simple training on the device and the test handling procedure.

The IVD CAPSULE Aeroallergen requires a lower sample volume, shorter assay time and can be performed at the point of care on capillary whole blood without any technical knowledge. All while maintaining excellent and comparable performances versus current laboratory gold standard tests.


1. de Azevedo, M. S. P. et al. Immunotherapy of allergic diseases using probiotics or recombinant probiotics. J Appl Microbiol 115, 319–333 (2013). 2. World Health Organization. Chronic Respiratory Diseases and Arthritis Team & WHO/WAO Meeting on the Prevention of Allergy and Allergic Asthma (2002 : Geneva, S. Prevention of allergy and allergic asthma. https://apps.who.int/iris/handle/10665/68361 (2003). 3. Putallaz, L., Bogaard, P. van den, Laub, P. & Rebeaud, F. Nanofluidics Drives Point-of-care Technology for on the Spot Protein Marker Analysis with Rapid Actionable Results. J Nanomed Nanotechnol 10, (2019). 4. Roethlisberger, S. et al. Novel Nanofluidic IgE Assay versus a Reference Method: A Real-World Comparison. Int Arch Allergy Immunol 180, 28–36 (2019).